EICHOR
● Active Not Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
Condition: Alzheimer Disease · Dementia · Brain Diseases · Sponsor: Eli Lilly and Company
About this study
The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including screening and follow-up is up to 93 weeks.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (141)
| Hospital Italiano de Buenos Aires | ABB, Argentina | — |
| Clinica Privada Banfield | Banfield, Argentina | — |
| Fundación para el Estudio y Tratamiento de Enfermedades Mentales (FETEM) | Buenos Aires, Argentina | — |
| Stat Research S.A. | Buenos Aires, Argentina | — |
| Centro de Investigaciones Metabólicas (CINME) | Buenos Aires, Argentina | — |
| CIPREC | Buenos Aires, Argentina | — |
| Mautalen Salud e Investigación | Buenos Aires, Argentina | — |
| Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada | Buenos Aires, Argentina | — |
| Centro Médico Arsema | Buenos Aires, Argentina | — |
| Instituto Geriatrico Nuestra Señora de Las Nieves | Buenos Aires, Argentina | — |
| Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) | Buenos Aires, Argentina | — |
| Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) | Buenos Aires, Argentina | — |
+ 129 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05508789